



Client/Matter No. 80248.0023.001
Express Mail Label No. EV322529420US
Attorney Docket No. ARR001 CIP

N THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Mark Munson, et al.	
Serial No.:	10/688,849	Art Unit: 1644
Filing Date:	October 15, 2003	Confirmation No.: 9448
Title:	P38 INHIBITORS AND METHODS OF USE THEREOF	Examiner: Not yet assigned

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. 1.56**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Sir:

Applicant hereby submits for filing under 37 CFR 1.97 a disclosure statement. In submitting these references, no representation is made or implied that the references are or are not material to the examination of this application. The patents, publications or other information of which Applicant is presently aware are listed in Form PTO/SB/08A submitted herewith and copies of all such patents and publications are attached hereto.

No fee is believed due for this submittal. However, any fee deficiency associated with this submittal may be charged to Deposit Account No. 50-1123.

Respectfully submitted,

Feb 6, 2004
Date


Sarah S. O'Rourke, Reg. No. 41,226
HOGAN & HARTSON LLP
One Tabor Center
1200 17th Street, Suite 1500
Denver, Colorado 80202
(720) 406-5385 Tel
(720) 406-5301 Fax



05 09-04

EXPRESS MAIL NO. EV322529420US

Attorney Docket No. ARR001 CIP

Client/Matter No.80248.0023.001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Mark Munson, et al.

Serial No. 10/688,849

Filed: October 15, 2003

For: P38 INHIBITORS AND METHODS
OF USE THEREOF

Art Unit: 1644

Examiner: Not yet accorded

Confirmation No.: 9448

CERTIFICATE OF MAILING BY EXPRESS MAIL

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The undersigned hereby certifies that the following documents:

1. Information Disclosure Statement Under 37 C.F.R. 1.56;
2. Information Disclosure Statement by Applicant, Form PTO/SB/08A (10/01);
3. Copies of 22 references;
4. Return postcard; and
5. Certificate of Mailing By Express Mail

relating to the above application, were deposited as "Express Mail," Mailing Label No. EV322529420USUS, with the United States Postal Service, addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Feb. 6, 2004
Date

Sarah O'Rourke
Mailer

Feb 6, 2004
Date

Sarah O'Rourke
Sarah O'Rourke, Reg. No. 41,226
HOGAN & HARTSON LLP
One Tabor Center
1200 17th Street, Suite 1500
Denver, Colorado 80202
(720) 406-5383 Tel
(720) 406-5301 Fax

PTO/SB/08A (10/01) (Substitute for form 1449A/PTO)		ATTY. DOCKET NO. ARR003 Client/Matter No.80248.0023.001		APPLICATION NO. 10/688,849	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) Sheet 1 of 2		FIRST NAMED INVENTOR Mark Munson			
		FILING DATE October 15, 2003		ART UNIT - 1644	

PTO

FEB 06 2004

PATENT & TRADEMARK OFFICE


U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document No. – Kind Code	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Doc	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	5,945,418	08-31-1999	Bemis et al.	
	2	6,080,763	06-27-2000	Regan et al.	
	3	6,093,742	07-25-2000	Salituro et al.	
	4	6,214,830 B1	04-10-2001	Beers et al.	
	5	6,228,881	05-08-2001	Regan et al.	
	6	6,242,453	06-05-2001	Cirillo et al.	
	7	6,297,381	10-02-2001	Cirillo et al.	
	8	6,358,945 B1	03-19-2002	Breitfelder et al.	
	9	6,432,995 B2	08-13-2002	Hickey et al.	
	10	6,479,507 B2	11-12-2002	Cheng et al.	
	11	6,503,930 B1	01-07-2003	Hanson et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Doc cntry code – No. – Kind Code	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Doc	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	TRANSLATION
						YES NO
	12	WO 97/12876	04-10-1997	Merck Co., Inc.		X
	13	WO 00/71535 A1	11-30-2000	Scios Inc.		X
	14	WO 01/02369 A2	01-11-2001	Agouron Pharmaceuticals, Inc.		X
	15	WO 02/42292 A2	05-30-2002	Scios, Inc.		X

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published

EXAMINER SIGNATURE	DATE CONSIDERED
--------------------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08A (10/01) (Substitute for form 1449A/PTO)		ATTY. DOCKET NO. ARR003 Client/Matter No.80248.0023.001		APPLICATION NO. 10/688,849		
<div style="text-align: center;">  </div> INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) Sheet 2 of 2		FIRST NAMED INVENTOR Mark Munson				
		FILING DATE October 15, 2003		ART UNIT - 1644		
U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	Document No. No. - Kind Code	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Doc	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Doc cntry code - No. - Kind Code	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Doc	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	TRANSLATION YES NO
	16	WO 02/072579	09-19-2002	Pfizer Products, Inc		X
	17	WO 03/032989 A1	04-24-2003	Boehringer Ingelheim Pharmaceuticals		X
	18	WO 03/051847 A1	06-26-2003	Smithkline Beecham		X
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No.	Include name of the author (In CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published				
	19	SALITURO, E.G., et al. "Inhibitors of p38 MAP Kinases: Therapeutic Intervention in Cytokine-Mediated Diseases," Current Medicinal Chemistry, 1999, 607-823.				
	20	FOSTER, M. L., et al., "Potential of p38 Inhibitors in the Treatment of Rheumatoid Arthritis," Drug News Perspect 13 (8), October 2000. pp 488-496.				
	21	BOEHM, J.D. and ADAMS, J. L. "Expert Opinion on Therapeutic Patents," 10:25-37 (2000).				
	22	NATARAJAN, SWAMINATHAN R., ET AL. "P38 MAP Kinase Inhibitors. Part 1: Design and Development of a New Class of Potent and Highly Selective Inhibitors Based on 3,4-Dihydropyrido, [3,2-d 1 Pyrimidone Scaffold," Bioorganic & Medicinal Chemistry Letters 13:273-276 (2003).				
EXAMINER SIGNATURE					DATE CONSIDERED	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						